1. Home
  2. TGHL vs MBAI Comparison

TGHL vs MBAI Comparison

Compare TGHL & MBAI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

TGHL

The GrowHub Limited Class A Ordinary Shares

N/A

Current Price

$0.31

Market Cap

10.5M

Sector

Technology

ML Signal

N/A

Logo Check-Cap Ltd. Ordinary Share

MBAI

Check-Cap Ltd. Ordinary Share

N/A

Current Price

$1.56

Market Cap

12.0M

Sector

N/A

ML Signal

N/A

Company Overview

Basic Information
Metric
TGHL
MBAI
Founded
2020
2004
Country
Singapore
Israel
Employees
N/A
85
Industry
EDP Services
Sector
Technology
Exchange
Nasdaq
Nasdaq
Market Cap
10.5M
12.0M
IPO Year
N/A
N/A

Fundamental Metrics

Financial Performance
Metric
TGHL
MBAI
Price
$0.31
$1.56
Analyst Decision
Analyst Count
0
0
Target Price
N/A
N/A
AVG Volume (30 Days)
21.1K
46.8K
Earning Date
05-18-2026
05-08-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
N/A
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$0.29
$1.31
52 Week High
$3.80
$3.92

Technical Indicators

Market Signals
Indicator
TGHL
MBAI
Relative Strength Index (RSI) 39.74 42.42
Support Level $0.29 $1.44
Resistance Level $0.51 $1.83
Average True Range (ATR) 0.03 0.12
MACD -0.00 -0.01
Stochastic Oscillator 10.81 19.45

Price Performance

Historical Comparison
TGHL
MBAI

About TGHL The GrowHub Limited Class A Ordinary Shares

The Growhub Ltd operates at the intersection of technology and supply chain management in the food industry, focusing on enhancing product traceability and authenticity. With a commitment to innovation and sustainability, It has developed a multi-faceted approach to address industry challenges. its business currently comprises two main divisions, which are the GrowHub Platform and its product trading facilitation offering.

About MBAI Check-Cap Ltd. Ordinary Share

Check-Cap Ltd is a clinical-stage medical diagnostics company engaged in the development of an ingestible imaging capsule that utilizes low-dose X-rays for the detection and imaging of colonic polyps and colorectal cancers, or CRC. The company is developing C-Scan, the first capsule-based system for preparation-free, colorectal cancer screening. Its scanning capsule will be swallowed and propelled by natural motility through the gastrointestinal tract and excreted naturally with no need for retrieval for data collection. The operations of the company are presently located in Israel, but it currently expects to market products in the United States, Europe, Israel and Japan.

Share on Social Networks: